A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT)

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT)

【24h】

A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT)

机译：在晚期乳腺癌（乳房）中，BN-BRACHYURY，ENTINOURY，ADO-TRASTUZUMAB OMUNSINE（T-DM1）和Bintrafusp Alfa（M7824）的顺序组合的相位IB试验（乳房）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
专利

1. A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT) [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：在晚期乳腺癌（乳房）中，BN-BRACHYURY，ENTINOURY，ADO-TRASTUZUMAB OMUNSINE（T-DM1）和Bintrafusp Alfa（M7824）的顺序组合的相位IB试验（乳房）
2. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-beta and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：Bintrafusp Alfa（M7824），一种双功能融合蛋白，靶向转化生长因子-β和编程死亡配体1，在先进的三阴性乳腺癌中：阶段1队列的初步结果
3. Identification of a tumor biomarker in advanced triple-negative breast cancer that predicts response to bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-beta and programmed death ligand 1 [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：鉴定高阴性乳腺癌中的肿瘤生物标志物，其预测Bintrafusp Alfa（M7824）的反应，双功能融合蛋白靶向转化生长因子-β和编程死亡配体1
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer [O] . Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, 2020

机译：ERBB2 mRNA表达和对HER2阳性乳腺癌中的ADO-TRASTUZIMAB OM存在（T-DM1）的反应
7. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q [O] . K.L. Jhaveri, X.V. Wang, V. Makker, 2019

机译：ADO-TRASTUZUMABAB emtansine（T-DM1）在患有乳腺癌和胃/胃肠道（GEJ）腺癌（GEJ）腺癌（GEJ）腺癌（GEJ）的患者中的患者：结果来自NCI匹配试验（EAY131）次级问题

A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT)

著录项

相似文献

相关主题

期刊订阅